Indian Pharma exports to US may increase in 2018, Care Ratings
The Dollar Business Bureau Despite many hurdles, pricing pressures and competition from other major pharma producing countries, India’s pharma exports to the US will in all likelihood increase in 2017-18. Drugs worth $50bn are expected to become off-patented this year giving enough room for pharma exports to get a boost, a report by Care Ratings revealed. The Indian Pharma industry is likely to face stiff competition from other countries to get Abbreviated New Drug Application(ANDA) approval. Other than this the pricing pressure is likely to increase in the generics market due to the consolidation of distribution channels and increase in competition the report detailed. However due to gain in the sales of generics drugs with branded drugs going off patent during 2017-19, will ...
Strides Shasun to divest its UK arm for Rs.240 cr
The Dollar Business Bureau Pharma firm Strides Shasun Ltd has taken a decision to divest its UK-based subsidiary Shasun Pharma Solutions Ltd (SPSL) to its current management for a value of £25 million (about Rs.240 crore). The company in a statement filed to BSE said, “The board of directors in a meeting on Tuesday cleared the divestment of SPSL, UK, to its current management team with investment by the Strides Shasun’s promoter group for an enterprise value of £25 million.” In 2006, Shasun had bought SPSL from Rhodia Pharma Solutions, a leading player in the domain of Contract Research Manufacturing Services (CRAMS). Since 2014, SPSL’s current management has shifted its focus from being a core CRAMS player to multiple industry domains including services, ...
India must be ready to meet growth in Bio-services sector: Expert
The Dollar Business Bureau The bio-services sector which is currently valued at US$ 5-6 billion is set to increase to US$ 50 billion soon and we should be prepared to meet this growth. V K Subburaj, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilisers, made the above statement at a round-table meeting on ‘Unleashing Opportunities in Bio-Services Including Contract Research & Manufacturing’, in New Delhi, on Friday. Stating that India makes pharmaceutical products worth US$ 30 billion every year and is a leading producer of generics, the Secretary expressed hope that the bio-pharmaceuticals will take over the sector in future. Speaking at the meet, the Secretary further stated that the conducive atmosphere for growth has been missing in ...
